A system for the production of silver-zinc oxide nanocomposites with anticancer and antimicrobial properties

Abstract

A system (100) for producing silver-zinc oxide nanocomposites with anticancer and antimicrobial properties, comprising: a) a silver nanoparticle synthesis unit (102) configured to produce silver nanoparticles from cow urine and silver nitrate solution; b) a zinc oxide nanoparticle synthesis unit (104) configured to produce zinc oxide nanoparticles from nutmeg seed extract and zinc acetate dihydrate; c) a nanocomposite forming unit (106) configured to mix the silver nanoparticles and zinc oxide nanoparticles in different weight ratios; d) a heat treatment unit (108) configured to calcine the mixed nanoparticles at temperatures between 600 °C and 800 °C; and e) a characterization unit (110) configured to analyze the structural, morphological and elemental properties of the synthesized nanocomposites.

Description

FIELD OF THE INVENTIONThe present disclosure relates to a system for making silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties.BACKGROUND OF THE INVENTIONNanotechnology has proven to be a path-breaking progress in cancer treatment and offers targeted and effective therapeutic solutions by the production of nanoparticles at the molecular level (1-100 nm). Among the various nanomaterials, zinc oxide (ZnO) and silver (Ag) nanoparticles have attracted great attention because of their exceptional anti-cancer properties. These include their ability to induce oxidative stress, induce apoptosis, and enhance the effectiveness of chemotherapy.Cancer is still one of the most common causes of death worldwide. According to the World Health Organization (WHO) and the Indian Council of Medical Research (ICMR), over 2.3 million people were afflicted with breast cancer in 2020. Conventional chemotherapeutic agents such as doxorubicin (Dox) are effective but often are associated with severe toxicity and drug resistance. This emphasizes the urgent need for innovative treatment approaches with higher efficacy and minimal side effects.ZnO nanoparticles have shown selective cytotoxicity against cancer cells by the formation of reactive oxygen species (ROS) and induction of apoptosis. Similarly, environmentally synthesized silver nanoparticles exhibited a strong anti-cancer and antimicrobial effect. Recent research has shown that silver-zinc oxide nanocomposites have enhanced anti-cancer effect due to their synergistic effects on cellular apoptosis and oxidative stress processes.Biological studies have shown that silver-zinc oxide nanocomposites, especially those with a silver content of 40%, have a remarkable anti-cancer activity against MCF-7 (breast cancer) and Caco-2 (colon cancer) cell lines and at the same time have minimal toxicity towards normal cells. Moreover, these nanocomposites exhibit a strong antimicrobial activity against pathogenic bacteria such as Staphylococcus aureusand Escherichia coliand thus counteract the growing threat of antibiotic-resistant bacterial infections. This dual function offers applications in both cancer treatment and infection control and makes them valuable candidates for next generation nanomedicine therapies.In view of the foregoing discussion, it is clear that there is a need to develop silver-zinc oxide nanocomposites. Therefore, the present invention provides a system for making silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties.SUMMARY OF THE INVENTIONThe present disclosure relates to a system for making silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties. The present invention provides a system for making silver-zinc oxide nanocomposites with improved anti-cancer and antimicrobial properties. The system comprises several integrated units for the synthesis of silver nanoparticles from cowurin, for the production of zinc oxide nanoparticles from coconut seed extract, for the mixing of these nanoparticles in different ratios, for the thermal treatment of the mixed material and for the characterization of the resulting nanocomposites. The system also provides opportunities for testing biological activity, thereby allowing a comprehensive assessment of the selective cytotoxicity of the nanocomposites against cancer cells and their antimicrobial efficacy against pathogenic bacteria.The present disclosure aims to provide a system for making silver-zinc oxide nanoparticles with anti-cancer and antimicrobial properties. The system comprises: a) a silver nanoparticle synthesis plant that produces silver nanoparticles from kuhrin and silver nitrate solution; b) a zinc oxide nanoparticle synthesis plant that produces zinc oxide nanoparticles from muskat seed extract and zinc acetate dihydrate; c) a nanocomposite formation plant that mixes silver and zinc oxide nanoparticles in different weight ratios; d) a heat treatment unit that calcining the mixed nanoparticles at temperatures between 600° C. and 800° C.; and e) a characterization unit that analyzes the structural, morphological, and elemental properties of the synthesized nanocomposites.An object of the present disclosure is to provide a system for making silver-zinc oxide nanoparticles with anti-cancer and antimicrobial properties.Another object of the present disclosure is a system for synthesizing silver-zinc oxide nanocomposites using green chemistry approaches with cowurin and muscatefish seed extract as natural precursors.Another object of the present disclosure is a system capable of producing silver-zinc oxide nanocomposites with optimal anti-cancer activity against breast and colon cancer cell lines while maintaining minimal toxicity to normal cells.Another object of the present disclosure is to provide a comprehensive system that enables the preparation, characterization and biological evaluation of nanocomposites with dual anti-cancer and antimicrobial functionality.Another object of the present disclosure is to establish a systematic approach to control the structural and functional properties of nanocomposites through precise mixing ratios and heat treatment parameters.In order to further clarify the advantages and features of the present disclosure, the invention will be explained in more detail with reference to specific embodiments that are illustrated in the accompanying drawings. These drawings illustrate only typical embodiments of the invention and are therefore not to be considered as limiting the scope thereof. The invention will be described and explained in more detail with reference to the accompanying drawings.BRIEF DESCRIPTION OF THE FIGURESThese and other features, aspects, and advantages of the present disclosure will become more fully understood when the following detailed description is read with reference to the accompanying drawings, in which like characters represent like parts throughout. The following applies here: FIG. 1 shows a block diagram of a system for making silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties, according to an embodiment of the present disclosure. FIG. 2 is a diagram illustrating the operation of the system for manufacturing silver-zinc oxide nanocomposites according to an embodiment of the present disclosure.Those skilled in the art will also appreciate that the elements in the drawings are shown for simplicity and are not necessarily to scale. For example, the flowcharts illustrate the method using the key steps to improve understanding of aspects of the present disclosure. In addition, regarding the construction of the apparatus, individual or multiple components of the apparatus may be represented by conventional symbols in the drawings. The drawings may only show the specific details relevant to understanding the embodiments of the present disclosure in order not to obscure the drawings with details readily apparent to those skilled in the art after the present description.DETAILED DESCRIPTION:In order to aid in the understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and will be described in an comprehensible manner. However, the scope of the invention is not limited thereby. Changes and further modifications of the illustrated system, as well as further applications of the principles of the invention, are possible, as would normally occur to a person skilled in the art.It will be understood by those skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.References throughout this specification to "one aspect," "another aspect," or similar language mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the phrases "in one embodiment," "in another embodiment," and similar phrases in this specification may or may not refer to the same embodiment.The terms "comprises," "comprising," or other variations thereof are intended to cover a non-exclusive inclusion, such that a process or method comprising a list of steps may include not only those steps, but also other steps not expressly listed or inherent in that process or method. Likewise, the phrase "comprises... for" one or more devices, subsystems, elements, structures, or components does not exclude, without further limitations, the existence of other devices, subsystems, elements, structures, components, or additional devices, subsystems, elements, structures, or components.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by one of ordinary skill in the art. The systems, methods, and examples provided herein are for illustrative purposes only and are not to be considered limiting.Embodiments of the present disclosure will be described in detail below with reference to the accompanying drawings.FIG. 1 shows a block diagram of a system ( 100) for manufacturing silver-zinc oxide nanoparticles with anti-cancer and antimicrobial properties according to an embodiment of the present disclosure.Referring to FIG. 1, the system (100) comprises: a) a silver nanoparticle synthesis unit (102) configured to produce silver nanoparticles from kuhrin and silver nitrate solution; b) a zinc oxide nanoparticle synthesis unit (104) configured to produce zinc oxide nanoparticles from muskat seed extract and zinc acetate dihydrate; c) a nanocomposite formation unit (106) configured to mix the silver nanoparticles and zinc oxide nanoparticles in different weight ratios; d) a heat treatment unit (108) configured to calcinate the mixed nanoparticles at temperatures between 600° C. and 800° C.; and e) a characterization unit (110) configured to analyze the structural, morphological, and elemental properties of the synthesized nanocomposites.In one embodiment, the silver nanoparticle synthesis unit (102) is configured to: a) mix filtered kuhrin with a silver nitrate solution, b) stir the mixture at ambient conditions at a predetermined rate, and c) centrifuge the resulting silver nanoparticles.In one embodiment, the zinc oxide nanoparticle synthesis unit (104) is configured to: a) break up nut seeds and soak in distilled water; b) heat the mixture to extract bioactive compounds; c) filter and evaporate the extract; and d) mix the extract with zinc acetate dihydrate while stirring at elevated temperature.In one embodiment, the nanocomposite-forming unit ( 106) is configured to mix silver nanoparticles with zinc oxide nanoparticles in weight ratios ranging from 10% to 50%.In one embodiment, the characterization unit (110): a) comprises an X-ray diffraction analyzer (XRD) configured to determine crystal structure and size; b) a UV-Vis spectrophotometer configured to measure absorption peaks at 360-380 nm; c) a Fourier Transform Infrared Spectrometer (FTIR) configured to identify functional groups; d) electron microscopy equipment configured to study morphology and structure; and e) energy dispersive X-ray spectroscopy (EDX) equipment configured to analyze the elemental composition.In one embodiment, the system (100) further comprises a bioactivity assay unit (112) for assessing a) anti-cancer activity against cancer cell lines and b) antimicrobial activity against bacterial pathogens. The bioactivity assay unit (112) comprises a) cell culture devices for obtaining cancer cell lines and normal cell lines; b) cytotoxicity evaluation devices for determining selective toxicity to cancer cells; and c) an antimicrobial test device for measuring anti-bacterial pathogen disease halos.In one embodiment, the system (100) further comprises a sample preparation unit (114) configured to prepare nanocomposite test solutions at various concentrations for biological testing.In one embodiment, the heat treatment unit (108) is configured to improve the structural and functional properties of the nanocomposites by controlled calcination.In one embodiment, the system is configured to produce nanocomposites having crystal sizes in the range of 8 nm to 26 nm.The present invention provides a comprehensive system for preparing silver-zinc oxide nanocomposites with improved anti-cancer and antimicrobial properties. The system is based on a silver nanoparticle synthesis plant that processes kuhrurin and silver nitrate solution to produce silver nanoparticles using an environmentally friendly chemistry approach. This unit mixes filtered kuhrin with a silver nitrate solution, stirs the mixture at room temperature at a controlled rate, and centrifuge to isolate the resulting silver nanoparticles. At the same time, a zinc oxide nanoparticle synthesis plant processes nut seeds to extract bioactive compounds that allow the formation of zinc oxide nanoparticles. This plant crushes and soaks coconut seeds in distilled water, heats the mixture to extract bioactive compounds, filters and evaporates the extract, and then mixes it with zinc acetate dihydrate with stirring at elevated temperature to form zinc oxide nanoparticles. The system then uses a nanocomposite-forming unit that precisely mixes the silver nanoparticles with zinc oxide nanoparticles in weight ratios of 10% to 50%, thereby forming various compositions having different biological activities. The mixed nanoparticles are then processed in a heat treatment unit that anneals the material at temperatures between 600° C. and 800° C. to improve structural integrity and functional properties. The resulting nanocomposites are then analyzed using a characterization unit equipped with X-ray diffraction analyzers, UV-Vis spectrophotometer, FT-IR spectrometers, electron microscopy equipment and energy dispersive X-ray spectroscopy systems to confirm their structural, morphological and elemental properties. The system also includes a bioactivity assay unit that evaluates anti-cancer activity against various cancer cell lines and antimicrobial activity against bacterial pathogens. This unit maintains cell cultures, evaluates cytotoxicity, and measures inhibitory zones to determine the biological activity of the synthesized nanocomposites. A sample preparation unit enables the preparation of nanocomposite test solutions in various concentrations for these biological tests. By the coordinated operation of these integrated units, the system produces nanocomposites having crystal sizes of 8 nm to 26 nm, which have selective toxicity to cancer cells and at the same time have antimicrobial properties. This creates a dual-functional nanomaterial with considerable potential for biomedical applications.FIG. 2 is a diagram illustrating the operation of the system for manufacturing silver-zinc oxide nanocomposites according to an embodiment of the present disclosure.Referring to FIG. 2, the system is configured to perform silver nanoparticle synthesis and zinc oxide nanoparticle synthesis and combine the two nanoparticles produced into synthesized silver zinc oxide nanoparticles with improved anti-cancer and antimicrobial properties.The apparatus for synthesizing silver nanoparticles is for preparing silver nanoparticles from filtered kuhrin and a silver nitrate solution. To this end, 3 ml of filtered kuhrin is mixed with 200 ml of a 0.01 M silver nitrate solution and stirred at 500 U / min under ambient conditions for six hours. The plant also has a centrifugation component which separates the synthesized silver nanoparticles at 10,000 U / min. The silver nanoparticles produced by this plant are characterized by means of UV-Vis spectroscopy, X-ray diffraction (XRD), Fourier transformation infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and transmission electron microscopy (TEM).The plant for synthesizing zinc oxide nanoparticles is designed for the synthesis of zinc oxide nanoparticles from coconut seed extract and zinc acetate dihydrate. The plant crushes fresh nut seeds and places them in distilled water. The mixture is then heated at 150° C. for 20 minutes. The heated extract is then filtered and evaporated at 40°C. The resulting extract is mixed with zinc acetate dihydrate and stirred at 60°C for two hours. The plant also has a centrifugation mechanism for isolating the resulting zinc oxide nanoparticles.The nanocomposite-forming unit is configured to mix silver nanoparticles with zinc oxide nanoparticles in different weight ratios of 10% to 50% as shown in Table 1 below. The resulting mixture is then transferred to a heat treatment unit for further processing. Table 1: Different weight ratios for the production of Ag-ZnO nanocomposite Table 1: Different weight ratios for the production of Ag-ZnO nanocompositeSilver-NPsZ 0100010 % Ag-ZnOZ 1109020 % Ag-ZnOZ 2208030 % Ag-ZnOZ 3307040 % Ag-ZnOZ 4406050 % Ag-ZnOZ 55050Zinc oxide-NPsZ 60100The heat treatment unit is configured such that the silver-zinc oxide nanoparticle mixtures are calcined at temperatures between 700° C. and 800° C. This unit is designed to improve the structural and functional properties of the nanocomposites during thermal processing.In one embodiment, the prepared nanocomposite is subjected to characterization, wherein characterization techniques, including UV-Vis spectroscopy, XRD, SEM, HRTEM, SAED, XRD spectroscopy, EDAX, and FT-IR, confirmed the structural, morphological, and elemental properties of the synthesized nanoparticles.The X-ray diffraction analyzer in the characterization unit is configured to determine the crystal structure and size of the synthesized nanocomposites. The analyzer confirms the hexagonal wurtzite structure of zinc oxide and recognizes characteristic peaks of metallic silver indicative of the presence of incorporated silver. The crystallite size determined using the Debye-Scherer equation is between 8.13 nm and 25.78 nm and influences the biological activity of the nanocomposites.The UV-Vis spectrophotometer is configured to measure the optical properties of the nanocomposites. Red-shifted absorption peaks in the range of 350-380 nm are observed, which indicate a narrowing of the band gap caused by silver incorporation. This supports improved charge carrier separation suitable for biomedical applications.The FTIR spectrometer is configured to identify functional groups in the synthesized nanocomposites. It detects ZnO stretching vibrations in the range of 400-600 cm -1 and additional peaks which arise as a result of the silver incorporation. Broad absorption peaks in the 3200-3600 cm -1 range indicate hydroxyl groups (-OH) which contribute to the stability and reactivity of the nanocomposites.Electron microscopy equipment includes both SEM and HRTEM systems. The SEM component is configured to examine the surface morphology and distribution of nanoparticles and to show uniform dispersion. The HRTEM component confirms the well dispersed structures and the variation of particle size.The EDX spectroscopy equipment is configured for analysis of the elemental composition of the nanocomposites. It confirms the successful incorporation of silver into the zinc oxide matrix, which correlates with the observed improvements in optical and antibacterial properties.In one embodiment, the system comprises a bioactivity assay unit for evaluating the anti-cancer and antimicrobial activity of the synthesized silver-zinc oxide nanocomposites (Ag-ZnO). The bioactivity assay unit comprises an antimicrobial testing device for evaluating the antibacterial activity of the Ag-ZnO nanocomposites. The antimicrobial testing apparatus is designed for use with the bacterial strains Escherichia coli(NCIM 2832) and Staphylococcus aureus(NCIM 2654), obtained from the National Centre for Cell Science (NCCS), Pune. The bacterial cultures are maintained in nutrient agar at 37°C. Agar plates containing the bacterial cultures are prepared and wells 6 mm in diameter are formed therein. Various concentrations of silver-zinc oxide nanocomposites (between 10 mg and 40 mg) are added to the wells. The plates are preincubated for 15 minutes at 15°C to allow diffusion of the nanocomposites into the medium and then incubated for 24 hours at 37°C. Antibacterial activity is determined by measuring the diameter of the inhibitor cavity in millimeters. The unit for testing bioactivity also comprises cell culture equipment and assessing cytotoxicity. The cell culture equipment is configured to culture the ATCC cell lines MCF-7 (breast cancer), Caco-2 (colon cancer) and Vero (normal kidney). Cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU / ml penicillin and 100 μg / ml streptomycin. The cells are maintained at 37°C in a humidified 5% carbon dioxide (CO 2) incubator until confluence is reached. Trypsinization is carried out with 0.05% trypsin and the cells are centrifuged at 1000 U / min for 5 minutes. The resulting pellet is resuspended in DMEM to obtain a cell suspension of 5.0×10 5 cells / ml.In one embodiment, the system comprises a sample preparation unit for preparing test solutions for biological tests. The sample preparation unit is configured to make a 3.7 mM stock solution of doxorubicin as a standard, which is serially diluted with simple medium to achieve final concentrations of 100 μM to 3.125 μM. The dilution sequence comprises the following steps:◯ 3.7 mM (> 8.1 μl 3.7 mM + 291.8 μl simple medium) > 100 μM◯ 100 μM→(150 μL of 100 μM+150 μL of simple medium)→50 μM◯ 50 μM→(150 μL 50 μM+150 μL simple medium)→25 μM◯ 25 μM→(150 μL 25 μM+150 μL simple medium)→12.5 μM◯ 12.5 μM→(150 μL 12.5 μM+150 μL simple medium)→6.25 μMThe sample preparation unit is also configured for preparing silver-zinc oxide nanocomposite test solutions for cytotoxicity evaluation. A 32 mg / ml stock solution of the nanocomposite is prepared in distilled water and serially diluted in neutral medium to achieve final concentrations of 100 μg / ml to 3,125 μg / ml. The diluting steps comprise the following steps:◯ 32 mg / ml→(30 μl 32 mg / ml+270 μl simple medium)→3.2 mg / ml◯ 3.2 mg / ml→(30 μl 3.2 mg / ml+270 μl simple medium)→320 μg / ml◯ 320 μg / ml→(93.75 μl of 320 μg / ml+206.2 μl of simple medium)→100 μg / ml◯ 100 μg / ml→(150 μl with 100 μg / ml+150 μl of pure medium)→50 μg / ml◯ 50 μg / ml→(150 μl with 50 μg / ml+150 μl of pure medium)→25 μg / ml◯ 25 μg / ml→(150 μl with 25 μg / ml+150 μl of pure medium)→12.5 μg / ml◯ 12.5 μg / ml→(150 μl with 12.5 μg / ml+150 μl of pure medium)→6.25 μg / ml6.25 μg / ml→(150 μl 6.25 μg / ml+150 μl simple medium)→3.125 μg / mlThe invention demonstrates that silver-zinc oxide nanocomposites have a significant anti-cancer and antimicrobial potential. The nanocomposites exhibited pronounced cytotoxicity against the cell lines MCF-7 (breast cancer) and Caco-2 (colon cancer), while showing less toxicity against normal Vero kidney cells. The incorporation of silver into zinc oxide altered the structural and optical properties, contributing to increased biological activity. Among the synthesized samples, the 40% Ag-ZnO nanocomposites exhibited the most marked anti-cancer effect.Characterization using techniques such as UV-Vis spectroscopy, X-ray diffraction (XRD), scanning electron microscopy (SEM), high resolution transmission electron microscopy (HRTEM), electron diffraction in selected regions (SAED), X-ray fluorescence spectroscopy (XRF), energy dispersive X-ray analysis (EDAX), and Fourier transform infrared spectroscopy (FT-IR) confirmed the structural integrity, morphological characteristics, and elemental composition of the nanocomposites.The Ag-ZnO nanocomposites also exhibited an effective antimicrobial activity against Staphylococcus aureusand Escherichia coli, emphasizing their multifunctional function. Compared to doxorubicin, the nanocomposites exhibited comparable anti-cancer activity with improved selectivity to cancer cells. The increased cytotoxicity is associated with structural and optical changes that are likely to interfere with the cellular functions essential for cancer cell viability.These results emphasize the utility of Ag-ZnO nanocomposites in biomedical applications. Their selective toxicity to cancer cells and their concomitant antimicrobial activity indicate a great potential in targeted cancer treatment and infection control. Further biological studies are recommended to emphasize clinical relevance and therapeutic optimization.The drawings and the foregoing description show examples of embodiments. Those skilled in the art will appreciate that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be divided into multiple functional elements. Elements of one embodiment may be added to another embodiment. For example, the order of the processes described herein may be changed and is not limited to the manner described herein. Moreover, the actions of a flow chart need not be performed in the order shown; nor do all actions necessarily need to be performed. Also, actions that are not dependent on other actions may be performed in parallel with the other actions. The scope of the embodiments is by no means limited by these specific examples. Numerous variations, whether or not explicitly stated in the specification, such as differences in structure, dimensions, and material use, are possible. The scope of the embodiments is at least as broad as recited in the following claims.Advantages, other advantages and solutions to problems have been described above with reference to specific embodiments. However, the advantages, merits, solutions to problems and any components that may result in an advantage, merit or solution being introduced or enhanced are not to be understood as critical, required or essential features or components of individual or all claims.REFERENCES100 A system for preparing silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties. 102 Silver nanoparticle synthesis unit 104 Zinc oxide nanoparticle synthesis plant 106 Nanocomposite formation unit 108 Heat treatment plant 110 Characterization unit 112 Bioactivity testing unit 114 Sample preparation unit 202 Antimicrobial activity against Gram positive and Gram negative bacteria Demonstrates 204 Anti-cancer activity Von Ag Nps, Zo Nps And 40% Ag-Zo 206MCF 7 CELL LINE CACO-2 CELL LINE VERO CELL LINE 208 100 Ml Myristica Fragrans / aqueous extract from Muscatnut seed + 6 G Zinc acetate dihydrate (Zn(NO 3)2.2 H 2 O)

Claims

A system (100) for making silver-zinc oxide nanocomposites having anti-cancer and antimicrobial properties, comprising: a) a silver nanoparticle synthesis unit (102) configured to make silver nanoparticles from kuhrin and silver nitrate solution; b) a zinc oxide nanoparticle synthesis unit (104) configured to make zinc oxide nanoparticles from muscatnut seed extract and zinc acetate dihydrate; c) a nanocomposite formation unit (106) configured to mix the silver nanoparticles and zinc oxide nanoparticles in different weight ratios; d) a heat treatment unit (108) configured to calciner the mixed nanoparticles at temperatures between 600°C and 800°C; and e) a characterization unit (110) configured to analyze the structural, morphological and elementary characteristics of the synthesized nanocomposites.The system (100) of claim 1, wherein the silver nanoparticle synthesis unit (102) is configured to: a) mix filtered kuhrin with a silver nitrate solution, b) stir the mixture at ambient conditions at a predetermined rate, and c) centrifuge the resulting silver nanoparticles.The system (100) of claim 1, wherein the zinc oxide nanoparticle synthesis unit (104) is configured to a) break up nut seeds and soak them in distilled water; b) heat the mixture to extract bioactive compounds; c) filter and evaporate the extract; and d) mix the extract with zinc acetate dihydrate while stirring at elevated temperature.The system (100) of claim 1, wherein the nanocomposite-forming unit (106) is configured to mix silver nanoparticles with zinc oxide nanoparticles in weight ratios ranging from 10% to 50%.The system (100) of claim 1, wherein the characterization unit (110) comprises: a) an X-ray diffraction analyzer (XRD) configured to determine crystal structure and size; b) a UV-Vis spectrophotometer configured to measure optical properties; c) a Fourier Transform Infrared Spectrometer (FTIR) configured to identify functional groups; d) electron microscopy equipment configured to study morphology and structure; and e) energy dispersive X-ray spectroscopy equipment (EDX) configured to analyze the elemental composition.The system (100) of claim 1, further comprising a bioactivity assay unit (112) configured to evaluate: a) the anti-cancer activity against cancer cell lines; and b) the antimicrobial activity against bacterial pathogens.The system (100) of claim 6, wherein the bioactivity assay unit (112) comprises: a) cell culture equipment configured to maintain cancer cell lines and normal cell lines; b) cytotoxicity evaluation equipment configured to determine selective toxicity to cancer cells; and c) an antimicrobial test device configured to measure zones of inhibition to bacterial pathogens.The system (100) of claim 1, further comprising a sample preparation unit (114) configured to prepare nanocomposite test solutions at different concentrations for biological testing.The system (100) of claim 1, wherein the heat treatment unit (108) is configured to improve structural and functional properties of the nanocomposites by controlled calcination.The system (100) of claim 1, wherein the system is configured to produce nanocomposites having crystal sizes in the range of 8 nm to 26 nm.

Images